Prosecution Insights
Last updated: November 12, 2026
Application No. 18/707,535

Ketone Precursors And Methods Therefor

Non-Final OA §103§112
Filed
May 03, 2024
Priority
Nov 04, 2021 — provisional 63/275,858 +1 more
Examiner
TRAN, LIEN THUY
Art Unit
1793
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Vdf Futureceuticals Inc.
OA Round
1 (Non-Final)
29%
Grant Probability
At Risk
1-2
OA Rounds
55%
With Interview

Examiner Intelligence

Grants only 29% of cases
29%
Career Allowance Rate
261 granted / 908 resolved
-36.3% vs TC avg
Strong +26% interview lift
Without
With
+26.5%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
72 currently pending
Career history
1000
Total Applications
across all art units

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This office action is in response to the election filed on 8/18/26. Upon further consideration, the election of species is withdrawn. All claims will be examined. Claims 1-4,7-10,13-23 and 35 are pending. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-4, 7-10,13-23 and 35 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In claim 1, the limitation “ a nutritionally acceptable carrier” is vague and indefinite because it’s unclear what would be considered as an nutritionally acceptable carrier; it’s unclear what is intended or encompassed in a “ carrier”. The specification does not disclose the ingredient for the nutritionally acceptable carrier. Also, the composition claimed in vague and indefinite. The claim recites the composition comprising a carrier in combination with a diester compound. However, it’s unclear what the form of the composition is; it’s unclear if the carrier is mixed with the compound or the carrier is coated over the compound or what. The recitation of “ combination” is unclear in denoting the form of the composition. On line 7, the limitation “ * denotes a chiral carbon atom” is vague and indefinite because it’s not clear what the “*” is point to. There is no “ *” in the structural formula. In claim 8, the limitation “ at least on of the chiral carbon atoms” is vague and indefinite because it’s not clear what chiral carbon atoms the claim is referring to. Claim 1 does not set forth any chiral carbon atoms. There is no recitation of multiple chiral carbon atoms. Claim 20 is vague and indefinite. The method reciting “ increasing (R)3-hydroxybutyrate”; however, it’s unclear what increasing encompasses. There is no frame of reference; increasing in comparison to what. The enzyme also recites “ enzymatic conversion” but it’s unclear if it’s an actual step because there is no recitation or any parameter defining enzymatic conversion. It’s unclear how this conversion is measured to determine the increase, what enzyme is needed for the conversion and what would be considered as an increase. The scope of the claim is unclear. ( For prior art application, the claim is interpreted as just comprising the step of administering the composition). In claim 23, the step of “ combining” , “ nutritionally acceptable carrier”, “ chiral carbon atom” have the same problem as claim 1. Also, the step “ formulating” is vague and indefinite because it’s unclear what processing step “ formulating” encompasses. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 1-4, 7-10,13-23,35 is/are rejected under 35 U.S.C. 103 as being unpatentable over Nelson ( 4701443) For claims 1-4,14,16,20, 23 and 35, Nelson discloses diester compound which are hydrolyzed by the tissue or intestinal flora to intermediate respiratory metabolites. The compound is provided in conventional parenteral solution along with other nutrients such as vitamins, electrolystes, trace metals and amino acids. These nutrients are considered the same as the claimed nutritionally acceptable carrier because the claims do not define any parameter to the carrier. The forming of solution inherently includes the step of combining the compound with the nutrients. The compound that the formula of G-(OOCACOOY)—nE where the G branched chain is as disclosed on column 2 line 25 through col. 3. The compound is formed by linking polyhydroxyl and polycarboxylic acids by bester bond. The A group is the residue of Krebs cycle carboxylic acid such as succinate, alpha-ketoglutarate, malate or oxaloacetate. The G has the structure ( QCOO) with different groups as shown in col. 4 lines 45-60. Preferably QCOO is the residue of a ketone body, e.g. acetoacetyl or 3 hydroxybutyryl. The polyesters must be hydrolyzed in the body after infustion or ingestion. Most likely hydrolysis is the primary result of enzymatic action in blood cells, plasma and body tissues and organs. Table 2 shows samples of compounds formed and administered as parenteral solution. The polyesters can be taken orally. Examples 1-4 show preparation of different polyester compounds. ( see col. 2-5,10-11, examples) Nelson does not disclose the specific hydrolysable form as in claim 1,10,23, the configuration as in claims 7-8, the enzyme as in claim 9, the intermediate as in claim 13, additional compound as claim 15, the form as in claim 17, the dosage as in claims 18-19,21-22 and the method of increasing as in claim 20. Nelson discloses diester compound having basic chemical structure as claimed. Different compounds can be formed by the use of different dicarboxylic acids and substitutions. Nelson also discloses that diester compounds hydrolyze in vivo after ingestion by enzymatic reaction. Thus, it’s obvious the hydrolysable intermediates can vary depending on the compounds formed and the hydrolyzing reaction in the body. Nelson discloses administering to mammal; thus, it’s obvious the enzyme lipase and esterase are present. It would have been obvious to have different configuration depending on the reaction. Such parameter can readily be determined by one skilled in the art. Nelson discloses the compound is given as an oral solution. However, Nelson also discloses that the compound can be given as component of ordinary meals. Thus, it would have been obvious to one of ordinary skill in the art to form the compound in other forms such as snack bar to be given during meal time. Nelson discloses on col. 11 lines 10-11 that the polyester concentration is not critical. Thus, it would have been within the skill of one in the art to determine the dosage that is optimum for nutritional and caloric benefits through routine experimentation. Nelson discloses other nutrients can be added to the solution. Thus, it would have been obvious to one of ordinary skill in the art to add other compounds. The specific compounds selected would depend on the nutritional needs and would be within the determination of one skilled in the art. Claim 20 is vague and indefinite as explained above. In any event, Nelson discloses administering the compound orally to mammal. Nelson discloses diester compound having basic chemical structure as claimed. Different compounds can be formed by the use of different dicarboxylic acids and substitutions. Nelson also discloses that diester compounds hydrolyze in vivo after ingestion by enzymatic reaction. Thus, it’s obvious the hydrolysable intermediates can vary depending on the compounds formed and the hydrolyzing reaction in the body. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to LIEN THUY TRAN whose telephone number is (571)272-1408. The examiner can normally be reached Monday-Thursday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Emily Le can be reached at 571-272-0903. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. October 25, 2026 /LIEN T TRAN/Primary Examiner, Art Unit 1793
Read full office action

Prosecution Timeline

May 03, 2024
Application Filed
Oct 28, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778171
BAKE-STABLE FILLING COMPOSITION
3y 3m to grant Granted Nov 03, 2026
Patent 12745788
METHOD FOR PREPARING LEGUMES POWDER USING AQUAFABA
2y 6m to grant Granted Sep 29, 2026
Patent 12690601
PLANT-BASED DELI MEAT ANALOGUE PRODUCTS COMPRISING TITANIUM DIOXIDE
1y 8m to grant Granted Jul 28, 2026
Patent 12648576
METHOD FOR PREPARING LINSEED MERINGUE FROM LINSEED
2y 10m to grant Granted Jun 09, 2026
Patent 12622437
Dual Textured Food
4y 1m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
29%
Grant Probability
55%
With Interview (+26.5%)
Low
PTA Risk
Based on 908 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month